Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Pipeline Review, H2 2016’, provides in depth analysis on Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AC Immune SA

AFFiRiS AG

BioArctic Neuroscience AB

Biogen Inc

Genmab A/S

Neuropore Therapies Inc

nLife Therapeutics SL

Primary Peptides, Inc.

Proclara Biosciences Inc

Prothena Corp Plc

QR Pharma Inc

reMYND NV

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Overview 9

Therapeutics Development 10

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Stage of Development 10

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Therapy Area 11

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Indication 12

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Companies 15

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Universities/Institutes 18

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development 26

AC Immune SA 26

AFFiRiS AG 27

BioArctic Neuroscience AB 28

Biogen Inc 29

Genmab A/S 30

Neuropore Therapies Inc 31

nLife Therapeutics SL 32

Primary Peptides, Inc. 33

Proclara Biosciences Inc 34

Prothena Corp Plc 35

QR Pharma Inc 36

reMYND NV 37

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles 38

ABL-301 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AV-1947D - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AV-1948D - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

AV-1949D - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

AV-1950D - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

AV-1950R - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BAN-0805 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BIIB-054 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

CLR-01 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

DPC-003 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Kenterin - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Monoclonal Antibody to Inhibit Alpha-Synuclein for Parkinson’s Disease - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

NLFPD-1233 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

NPT-088 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

NPT-20011 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

NPT-289 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

NPT-3G - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

NPT100-18A - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

PD-01 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

PD-03 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

PD-04 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Posiphen - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

PP-003 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

PRX-002 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

quinpramine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

ReS-12S - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

ReS-9S - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

trehalose - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Vaccine to Target Alpha-Synuclein for Parkinson's Disease - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Projects 79

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Featured News & Press Releases 81

Nov 18, 2016: Proclara Biosciences Awarded Part the Cloud Grant from Alzheimer’s Association to Support Development of NPT088 for Alzheimer’s Disease 81

Nov 16, 2016: Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders 81

Nov 09, 2016: Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease 82

Sep 07, 2016: Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer’s Disease 83

Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11 83

Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials 84

Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference 84

Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer’s Association International Conference 85

Jul 02, 2015: BIIB054 reached significant milestone 85

Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease 85

Jun 15, 2015: BioArctic Neuroscience Parkinson’s disease program receives grant from VINNOVA 86

Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders 87

Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson’s disease 87

Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease 87

Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer’s & Parkinson’s Diseases 89

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by AC Immune SA, H2 2016 26

Pipeline by AFFiRiS AG, H2 2016 27

Pipeline by BioArctic Neuroscience AB, H2 2016 28

Pipeline by Biogen Inc, H2 2016 29

Pipeline by Genmab A/S, H2 2016 30

Pipeline by Neuropore Therapies Inc, H2 2016 31

Pipeline by nLife Therapeutics SL, H2 2016 32

Pipeline by Primary Peptides, Inc., H2 2016 33

Pipeline by Proclara Biosciences Inc, H2 2016 34

Pipeline by Prothena Corp Plc, H2 2016 35

Pipeline by QR Pharma Inc, H2 2016 36

Pipeline by reMYND NV, H2 2016 37

Dormant Projects, H2 2016 79

Dormant Projects (Contd..1), H2 2016 80

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports